FIELD: pharmacology.
SUBSTANCE: group of inventions is a pharmaceutical composition for use in treatment of Parkinson's disease comprising a pharmaceutically acceptable carrier and a combination of fixed-dose pramipexole and rasagiline; and a method for production of a sustained release formulation comprising a combination of pramipexole and rasagiline or a pharmaceutically acceptable salt thereof with fixed doses thereof. This combination with fixed doses contains 0.05 to 1.0 mg of pramipexole and 0.055 to 1.0 mg of rasagiline.
EFFECT: group of invention allows to reduce the amount of side effects while maintaining high efficiency of the pharmaceutical composition by reducing the dose of pramipexole and maintaining a high dose of rasagiline.
19 cl, 4 dwg, 6 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PARKINSON'S DISEASE THERAPY USING COMBINATION WITH FIXED DOSAGES | 2013 |
|
RU2771522C2 |
| RASAGILINE COMPOSITIONS OF PROLONGED RELEASE AND USE THEREOF | 2011 |
|
RU2607595C2 |
| RASAGILINE COMPOSITIONS WITH PROLONGED RELEASE AND USE THEREOF | 2011 |
|
RU2734632C2 |
| PHARMACEUTICAL COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | 2009 |
|
RU2540470C9 |
| PHARMACEUTICAL COMPOSITION IN FORM OF SINGLE ORAL DOSE CONTAINING LEVODOPA, CARBIDOPA AND ENTACAPONE, OR SALTS THEREOF | 2009 |
|
RU2519159C2 |
| PROLONGED-RELEASE PHARMACEUTICAL COMPOSITION OF ENTACAPONE OR ITS SALTS | 2009 |
|
RU2540465C2 |
| ORAL PHARMACEUTICAL COMPOSITION SUITABLE FOR IMPROVING EFFECTIVENESS OF TREATMENT OF MOTOR DISORDERS | 2013 |
|
RU2670272C2 |
| NEW PHARMACEUTICAL COMPOSITION OF TAMSULOZIN AND DUTASTERIDE | 2019 |
|
RU2795928C2 |
| PHARMACEUTICAL COMPOSITIONS OF ACOTIAMIDE AND PROTON PUMP INHIBITOR | 2019 |
|
RU2820820C2 |
| METHOD FOR TREATING MOVEMENT DISORDERS WITH BEFIRADOL | 2015 |
|
RU2702101C2 |
